Intact Investment Management’s Medicenna Therapeutics Corp. Common Shares MDNA Stock Holding History

Intact Investment Management’s Portfolio MDNA Stock Details MDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-73,900	Closed	-$117K	–	272
2022 Q1	$117K	Sell	73,900 -285,900	-79%	-$444K	﹤0.01%	253
2021 Q4	$752K	Sell	359,800 -25,800	-7%	-$53.5K	0.02%	218
2021 Q3	$1.29M	Hold	385,600	–	–	0.04%	180
2021 Q2	$1.43M	Hold	385,600	–	–	0.04%	173
2021 Q1	$1.96M	Buy	+385,600	New	+$1.57M	0.06%	167

Other funds holding MDNA

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

WVP

Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

LBA

Letko, Brosseau & Associates Montreal, Quebec, Canada $6.2B AUM 38.92% 1-Year Est. Return

MCWS

McKinley Carter Wealth Services Wheeling, West Virginia $1.94B AUM 20.7% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Intact Investment Management's MDNA Position: Q2 2022 in Review

Intact Investment Management sold out of Medicenna Therapeutics Corp. Common Shares (MDNA) in Q2 2022, closing a stake of 73,900 shares — an estimated $117K sold.

Intact Investment Management first reported a position in MDNA in Q1 2021 and held it in 5 quarters. The position peaked at $1.96M in Q1 2021. 19 funds tracked by Wall St. Rank hold MDNA as of Q2 2022.

Intact Investment Management reported no remaining Medicenna Therapeutics Corp. Common Shares position as of Q2 2022 after selling out during the quarter.
Intact Investment Management sold 73,900 Medicenna Therapeutics Corp. Common Shares shares in Q2 2022, an estimated $117K.
Intact Investment Management first reported a position in Medicenna Therapeutics Corp. Common Shares in Q1 2021 and held it in 5 quarters.
Intact Investment Management's Medicenna Therapeutics Corp. Common Shares position peaked at $1.96M in Q1 2021.
19 funds tracked by Wall St. Rank held Medicenna Therapeutics Corp. Common Shares as of Q2 2022.

Based on Intact Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.